| 4 0.01 (0.25%) | 01-08 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.57 | 1-year : | 6.5 |
| Resists | First : | 4.76 | Second : | 5.57 |
| Pivot price | 1.28  |
|||
| Supports | First : | 1.94 | Second : | 0.2 |
| MAs | MA(5) : | 3.29 |
MA(20) : | 1.07 |
| MA(100) : | 0.97 |
MA(250) : | 4.4 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 83.7 |
D(3) : | 80.8 |
| RSI | RSI(14): 84.6 |
|||
| 52-week | High : | 10.47 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MLEC ] has closed below upper band by 9.6%. Bollinger Bands are 765.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.13 - 4.15 | 4.15 - 4.17 |
| Low: | 3.71 - 3.73 | 3.73 - 3.75 |
| Close: | 3.95 - 3.99 | 3.99 - 4.02 |
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
Mon, 05 Jan 2026
What Moolec’s 15-for-1 share consolidation means for investors - Stock Titan
Wed, 31 Dec 2025
What Moolec Science’s 15-for-1 share consolidation means for holders - Stock Titan
Tue, 23 Dec 2025
Moolec receives Nasdaq non-compliance letter - MSN
Tue, 16 Dec 2025
Moolec Science Approves Share Consolidation and Governance Changes - TipRanks
Thu, 11 Dec 2025
Moolec Science Scales GLASO U.S. Platform With Record 2025 Campaign and Expansion Into Nutrition & Supplements Market - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 21 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -31.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 5.7 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|